Patients admitted to Australian hospitals for heart failure with reduced ejection fraction consistently miss out on lifesaving guideline-recommended therapies, leading cardiologists warn.

Among other serious shortcomings, almost half of those with heart failure with reduced ejection fraction (HFrEF) eligible for an aldosterone antagonist did not receive one upon discharge, according to results from the first-of-its-kind study.